OBJECTIVES: Between January 2007 and September 2014 NICE report that they have made 65 health technology assessment decisions categorized by them as a "recommended in line with clinical practice" (RiLwCP). This categorization is not explained and implications for patient access are not clear. Using a previously developed method, we calculate the degree of recommended access for these decisions. In order to facilitate understanding we also develop a taxonomy for the factors underlying these decisions. METHODS: In a previously published paper we developed a measure, M, to summarize access associated with NICE technology optimized appraisal decisions. This was defined as M= (p/P)X100, where M is a measure of the level of patient access (0 equals no access, 100 full access), P is the set of patients considered in the guidance as potential candidates for treatment (given the scope of appraisal and license), and p is the number of patients for whom NICE did recommend. We applied measure M to the 65 RiLwCP decisions made between January 2007 and September 2014. Then assessing the guidance documents published for these decisions we identified six themes driving specific recommendations: reference to a previous NICE TA, existence of a relevant clinical guideline, the technology fits within an established pathway of care, clinical opinion, clinical/costeffectiveness matching, non-pharmaceutical. RESULTS: for 65 decisions between January 2007 and september 2014 m was 66. Among the factors underlying RiLwCP decisions the most common were instances where the committee matched cost and clinical effectiveness evidence, doing so in 37% of cases. CONCLUSIONS: The results for this period suggest that many RiLwCP decisions have the same characteristics as those classified as "optimized" by NICE; notably that use is restricted to a subgroup of patients relative to license and this is done for clinical and/or cost effectiveness considerations. OBJECTIVES: G-BA and NICE are two influential HTA agencies: both are large markets for pharmaceuticals, many countries look to Germany for reference pricing, and NICE decisions are referenced in other agencies' assessments. Both agencies review clinical efficacy versus a comparator. NICE also evaluates the cost-effectiveness. The output of a G-BA review is the "additional benefit" score, while for NICE it is an incremental cost-effectiveness ratio (ICER). Because both outcomes are dependent on the clinical evaluation, we hypothesize that G-BA's additional benefit score and NICE's ICER is inversely related. The relationship between NICE and G-BA is useful for manufacturers trying to predict reimbursement in these markets and globally. Our objective is to examine how G-BA's additional benefit decision correlates to NICE's reimbursement decision and to the most probable incremental cost-effectiveness ratio (ICER). METHODS: G-BA assessments were matched to NICE final guidances. G-BA's additional benefit was extracted and compared to the NICE reimbursement decision (categorized as positive or negative) and the ERG's most probable ICER. In instances where there were multiple ICERs reported (e.g. due to different comparators), the lowest ICER was used. If a drug "dominated" the comparator, an ICER of 0 was used. RESULTS: 138 G-BA additional benefit decisions were compared to 34 NICE final guidelines. 56% the G-BA assessments resulted in a "no additional benefit" score and the second most prevalent score was "minor additional benefit" (20%). 82% of NICE decisions were positive. There was no difference in the distribution of additional benefit scores by NICE decision. There was not a strong correlation between additional benefit and the ICER (r= 0.09). CONCLUSIONS: There does not appear to be a trend for G-BA to issue better additional benefits to drugs with a positive NICE decision and for drugs with a better additional benefit decision to have a lower ICER.
OBJECTIVES:
The analysis was conducted to compare trends in recommendations for orphan and non-orphan products reviewed by the Scottish Medicines Consortium (SMC), the National Institute of Health and Care Excellence (NICE) and the Gemeinsamer Bundesausschuss (G-BA), and identify disease areas that may be particularly challenging for manufacturers planning European product launches. METHODS: The following were categorized as 'recommended': NICE and SMC positive and restricted recommendations, G-BA major, minor and considerable additional benefit decisions; and 'unable to recommended': NICE negative recommendations, SMC negative recommendations and non-submissions, G-BA no-benefit or unquantifiable benefit. Analysis of products by disease area was conducted by classification into British National Formulary (BNF) categories. RESULTS: SMC, NICE and G-BA have published 1160, 147 and 100 recommendations since their formation. Positive recommendations from NICE/SMC have increased in 2012-2014 (58% to 74%) but decreased from G-BA (50% to 43%). Treatments for malignant disease and immunosuppression formed the largest category of submissions (SMC 244, NICE 70, G-BA 34) with higher recommendation rates in Germany (65%) than the UK (50%). Significant differences in recommendations between the UK and Germany were found in endocrine treatments (73% vs. 24%, p= 0.00003) and eye treatments (74% vs. 20%, p= 0.012). In 2011-2014, NICE and G-BA only evaluated 9 and 16 orphan products, respectively. Overall, NICE has recommended more orphan products (67%) than G-BA (63%) or SMC (49%). NICE and SMC recommendations for orphan products have increased in 2014 compared to previous years. CONCLUSIONS: This analysis illustrates that the UK market may be easier to access than the German market but the scale of the challenge depends on the BNF category of the treatment. The next stage of analysis will consider trend analysis when accounting for SMC resubmissions and the re-review of NICE technology appraisals and multiple technology appraisals.
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OBJECTIVES:
The statutory health insurance in Germany comprises 90% of the German population covering nearly all healthcare services with only little copayments. German health insurance claims data therefore constitute an important basis for real world evidence (RWE) on epidemiology and cost information. Aim of this study was to investigate to which extent RWE was used for estimation of prevalence and incidence in German AMNOG assessments since introduction 4 years ago and also its impact on price discounts. METHODS: German AMNOG assessments submitted until December 2014 were evaluated. They were screened for use of RWE in assessing prevalence and incidence and also target populations. After description and discussion of methods and data sources used, statistics were applied to explore a potential influence of use and quality of RWE data on price discounts. RESULTS: In total, 108 AMNOG dossiers were included. Real world evidence was used in 42.6% of these dossiers to assess prevalence and incidence as well as target populations. German claims data were employed in 8 dossiers (7.4%), registry data in 7 dossiers (6.5%), other data sources like Delphi panels in 37 dossiers (34.3%). The impact of quality of RWE evidence on negotiated discounts is inconclusive with limited data available. German claims data comprise comprehensive information such as demographics, outpatient and inpatient care, prescriptions, devices and aids, incapacity to work and sick leave payments. The routine documentation of diagnoses, procedures and prescriptions as well as the ability to evaluate patient histories are particularly useful for prevalence and incidence analyses, especially regarding the target population and cost estimations which are of paramount importance in price negotiations following the AMNOG assessment. CONCLUSIONS: German claims data constitute a valuable and valid data source for assessing epidemiologic evidence in German AMNOG assessments. Indication specific claims data analyses are a meaningful complement to literature research. OBJECTIVES: Meta-analysis (MA) of time to event survival data are most commonly performed using the individual summary statistic hazard ratio from each study, as an appropriate measure of effect. Currently there is no clear guidance regarding alternative novel methodologies of evidence synthesis using survival data which violates the proportional hazards (PH) assumption. The aim of this study was to assess: (i) the guidance from HTA bodies in relation to the MA of time to event survival data; (ii) technology assessments (TAs) submitted to NICE to determine the level of supporting information relating to the PH assumption accompanying MAs of time to event data in manufacturer submissions, and the response of reimbursement authorities. METHODS: HTA authorities guidelines (NICE, PBAC, IQWIG, CADTH, NCPE) were searched to identify information relating to the MA of time to event data. The NICE website was interrogated to identify TAs and the associated ERG/FAD reports in the oncology setting (published 2011-2014) reporting MAs of time to event data. RESULTS: Of the guidelines searched, the NICE, PBAQ and IQWIG guidelines for evidence synthesis refer to the consideration of the proportional hazards assumption when performing MA of time to event survival data. Of the most recent 60 NICE TAs, seven included the analysis of time to event data, however none commented upon the PH assumption. CONCLUSIONS: The impact of failing to consider the validity of the PH assumption for MA of time to event data in manufacturer submissions is unclear. The failure of trialists and statisticians to investigate the validity of the PH assumption for time to event data used in evidence synthesis may result in clinical decisions based on inappropriate methods.
